Jewell M. Christopher's Insider Trades & SAST Disclosures
Jewell M. Christopher's most recent trade in Cartesian Therapeutics Inc was a trade of 9,000 Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on Jan. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jewell M. Christopher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.23 per share. | 10 Jan 2025 | 9,000 | 62,490 (0%) | 0% | 3.2 | 29,070 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 9,000 | 67,432 | - | - | Stock Option (Right to Buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 03 Jan 2025 | 1,286 | 53,490 (0%) | 0% | 16.8 | 21,646 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.72 per share. | 03 Jan 2025 | 1,264 | 54,776 (0%) | 0% | 16.7 | 21,136 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,400 | 47,400 | - | - | Employee Stock Option (right to buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 16,100 | 56,040 (0%) | 0% | 0 | Common Stock | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.23 per share. | 20 Nov 2024 | 14,000 | 39,940 (0%) | 0% | 3.2 | 45,220 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 14,000 | 76,432 | - | - | Stock Option (Right to Buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.23 per share. | 14 Nov 2024 | 36,050 | 61,990 (0%) | 0% | 3.2 | 116,442 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2024 | 36,050 | 106,497 | - | - | Stock Option (Right to Buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.34 per share. | 14 Nov 2024 | 18,550 | 43,440 (0%) | 0% | 16.3 | 303,126 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 14 Nov 2024 | 17,500 | 25,940 (0%) | 0% | 17.0 | 297,824 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2024 | 16,065 | 90,432 | - | - | Stock Option (Right to Buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 14 Nov 2024 | 16,065 | 25,940 (0%) | 0% | 17.1 | 274,093 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.23 per share. | 14 Nov 2024 | 16,065 | 42,005 (0%) | 0% | 3.2 | 51,890 | Common Stock |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 142,547 | 142,547 | - | - | Stock Option (Right to Buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 4,276 | 0 | - | - | Stock Option (Right to Buy) | |
| Selecta Biosciences Inc | Jewell M. Christopher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 998,000 | 998,000 | - | - | Employee Stock Option (right to buy) | |
| Selecta Biosciences Inc | Jewell Christopher M. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 778,200 | 778,200 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges